| 8.2 -0.11 (-1.32%) | 06-20 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.04 | 1-year : | 12.89 |
| Resists | First : | 9.45 | Second : | 11.04 |
| Pivot price | 8.56  |
|||
| Supports | First : | 7.81 |
Second : | 6.8 |
| MAs | MA(5) : | 8.47  |
MA(20) : | 8.28 |
| MA(100) : | 7.44 |
MA(250) : | 22.04 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 57.8 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 61.9 | Low : | 4.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CRBP ] has closed above bottom band by 34.4%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.47 - 8.53 | 8.53 - 8.57 |
| Low: | 7.98 - 8.04 | 8.04 - 8.1 |
| Close: | 8.22 - 8.31 | 8.31 - 8.39 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Tue, 17 Jun 2025
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
Thu, 22 May 2025
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Thu, 22 May 2025
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
Mon, 19 May 2025
Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming - Stock Titan
Tue, 06 May 2025
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance
Tue, 06 May 2025
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 1,890 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -4.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.39 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.2 % |
| Return on Equity (ttm) | -44.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.44 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -1.94 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|